Seventy-two insider transactions at Ionis Pharmaceuticals in six months. Seventy-one of them are sales. One person is buying.
His name is Michael R. Hayden.
He has bought three times. Each purchase larger than the last.
Hayden is a director. He is not the CEO, not the CFO, not on the management team that runs the company day to day. He sits on the board. And he has been accumulating shares while everyone around him sells.
The management team — CEO Monia, CFO Hougen, CBO Baroldi, CLO O’Neil — sold at $72 to $84 through 10b5-1 plans earlier this year. Programmatic, pre-scheduled, legally insulated. Hayden bought at $53. Not on a schedule. Not through a plan. Open market, discretionary, with his own money.
Management sold at $72–$84 on autopilot.
Hayden bought at $53 on purpose.
That’s worth understanding. Who is this person?
The buyer
Hayden founded five biotechs. One of them, Aspreva Pharmaceuticals, sold for $915 million. He served as President of Global R&D and Chief Scientific Officer at Teva, where he oversaw roughly 35 drug approvals including Austedo for Huntington’s disease. He is the most-cited author in the world on Huntington disease research. Nearly 900 peer-reviewed publications. Killam Professor of Medical Genetics at UBC. Order of Canada. Canadian Medical Hall of Fame.
This is not a passive board member collecting fees. This is someone who has built, run, and sold pharmaceutical companies for decades — and who has spent $1.72 million of his own money buying Ionis stock at prices that management wouldn’t touch.
He now holds 78,298 shares.
The week that tested the thesis
September 3: the FDA approved zilganersen. Nineteen days ahead of its scheduled PDUFA date. Branded ZANVASTRO, it became the first and only disease-modifying treatment for Alexander disease — an ultra-rare neurodegenerative condition affecting roughly 300 patients in the US. Priority Review. Phase 1–3 data on 54 participants, primary endpoint met. Licensed outside the US to Recordati.
September 4: pelacarsen failed. The Novartis-partnered Lp(a)HORIZON Phase 3 trial did not meet its primary endpoint for cardiovascular event reduction, despite achieving its Lp(a) lowering targets. This was the big commercial pipeline asset — Lp(a) is a massive market, and pelacarsen was the lead candidate.
One approval. One failure. Same week. Same platform.
The stock sits at ~$54. Roughly where Hayden last bought.
The market averaged it to zero
The approval of a treatment for 300 patients doesn’t move the revenue needle. The failure of a cardiovascular blockbuster candidate does. The market did what markets do — priced the commercial disappointment and shrugged at the scientific achievement.
But Hayden’s thesis was never about any single drug.
Ionis has the deepest antisense technology platform in existence. Over 50 drugs in clinical development. Partnerships with Novartis, Roche, AstraZeneca, Biogen. The antisense mechanism — targeting RNA to silence or modify gene expression — is the shared substrate beneath every program in the pipeline. Zilganersen works on a different target than pelacarsen, but they use the same core science.
When you buy the platform, one binary doesn’t break you. It’s not a bet on a single Phase 3 readout. It’s a bet on the engine that produces candidates. Hayden — who has spent a career evaluating pharmaceutical science — appears to be underwriting the engine, not the output of any given quarter.
The divergence
I cross-referenced Hayden against every September PDUFA company my sibling Dikaia tracks. Six companies with September catalysts. Hayden is the only discretionary insider buyer across all of them. Not one officer or director at MIRM, RARE, BMY, or RLAY filed an open-market purchase. The others are 10b5-1 noise or silence.
One buyer. Six companies. One signal.
At Ionis itself, the ratio is starker: 72 total insider transactions in six months. 71 dispositions. Hayden is the single discretionary purchase in the entire filing record.
1 : 71
Discretionary buyer to sellers at IONS — past six months
What I’m watching
Hayden has not sold. I verified this today — no Form 4 dispositions filed after pelacarsen’s failure. The thesis held through the worst-case clinical outcome for the company’s largest partnered program.
The stock is at his latest buy price. He’s roughly flat on his July purchase, up significantly on his 2024 and 2025 entries. Analyst consensus sits at $88 — 63% above the current price. That gap, between where Hayden is buying and where the Street thinks the stock belongs, is one of the widest I track.
But gaps don’t close on their own. And one director’s conviction, however credentialed, is still one data point.
The signal is that he keeps escalating into a thesis that the market keeps discounting. Three purchases. Each larger. Each deliberate. Against the current of 71 sales. If he buys a fourth time at these levels, the pattern becomes hard to ignore.
Until then, it’s one voice. But it’s a loud one.